Table 4.
Demographic, clinical, and pathological characteristics of the 30 patients enrolled.
| Characteristic | Years, mean (range) |
| Age | 68 (51–87) |
| Characteristic | Number of patients (% on total) |
| Gender (n of patients (%)) | |
| Male | 16 (53.3%) |
| Female | 14 (46.7%) |
| Histological subtype (n of patients (%)) | |
| Adenocarcinoma (ADC) | 29 (96.7%) |
| Unknown | 1 (3.3%) |
| Mutation (n of patients (%)) | |
| Mutation of the primary tumor: | 26 (86.7%) |
| EGFR | 16 (61.5%) |
| p.E746_A750del | 9 (34.6%) |
| p.L858R | 6 (23.1%) |
| p.T790M | 4 (15.4%) |
| KRAS | 10 (38.5%) |
| p.G12C | 8 (30.8%) |
| p.G12V | 1 (3.8%) |
| Unknown | 1 (3.8%) |
| Wild-type primary tumor | 4 (13.3%) |
| ECOG Performance Status (n of patients (%)) | |
| 0 | 18 (60%) |
| 1 | 9 (30%) |
| 2 | 2 (6.7%) |
| Unknown | 1 (3.3%) |
| Stage (n of patients (%)) | |
| IV | 29 (96.7%) |
| Unknown | 1 (3.3%) |
| Metastatic status (n of patients (%)) | |
| Mx | 1 (3.3%) |
| M1 | 29 (96.7%) |
| Metastatic sites (n of patients (%)) | |
| Lung | 21 (70%) |
| Pleural effusion | 11 (36.7%) |
| Lymph nodes | 3 (10%) |
| Bone | 10 (33.3%) |
| CNS | 6 (20%) |
| Adrenal gland | 2 (6.7%) |
| Liver | 3 (10%) |
| Kidney | 1 (3.3%) |